skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

医療機器市場をリアルタイム分析

Meddevicetracker | Pharma intelligence

Meddevicetracker(メッドデバイストラッカー)を使用することで、競争の激しい医療機器市場での優位性を維持できます。医療機器、診断、高度な配信システムに関して競合製品の評価、重要なイベントの追跡、より的確な情報に基づく意思決定が可能になります。

  • 医療機器市場の競合状況を疾患や機器の種類から把握
  • 研究開発や臨床試験の履歴
  • 医薬品と医療機器または医薬品と診断の組み合わせ
  • 製品、イベントでの検索機能
  • 市場調査レポート、売上予測、メーカーシェアへのアクセス

 

Meddevicetrackerを活用することで以下のことが可能です:

競合分析
自社の開発候補品と競合する開発中の医療機器は?医薬品の投与方法に関して、競合企業の動向を把握したい。

臨床試験
対象領域の臨床試験の情報や進捗を把握する

開発履歴
製品別にこれまでの開発経緯を時系列で追うことができ、今後の動向を推測できます。

検索機能
イベントや今後のマイルストーン、対象となる医療機器を把握しモニタリング

市場分析
医療機器の市場トレンドを理解し、成長が見込めるマーケットを探る。医療機器の市場性を評価したい。また、各企業の売上やマーケットシェアに関するレポートも入手できます。

 

Meddevicetrackerの対象範囲:

  • 心血管系
  • コンパニオン診断
  • 避妊、不妊
  • 糖尿病、肥満
  • ドラッグデリバリー
  • 塞栓性脳卒中予防
  • 止血
  • 腫瘍学
  • 整形外科
  • 痛み
  • 静脈血栓塞栓症
  • 創傷治癒

無料の最新記事&レポート

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    EU Reforms Must Heed Pandemic Lessons

    Covid19 Eu reforms

    Reforms set out by the European Commission to better prepare the EU for future health crises must heed key lessons learned from experiences of the COVID-19 pandemic, such as the benefits of digitalization, Medicines for Europe has urged.

    Topic Coronavirus EU Policy & Regulation

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Glenmark Debuts Favipiravir For COVID-19 In India

    Glenmark has received the go-ahead in India for and launched its low-priced favipiravir product for mild to moderate COVID-19 under an accelerated approval process.

    Topic Coronavirus drug-review

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Generics Industry Experiences Extraordinary First Quarter Due To COVID-19 Crisis

    Coronavirus-induced stockpiling and advanced prescribing of medicines has resulted in generics companies across the world registering unprecedented growth during the first quarter of 2020. However, many companies predict sales will level off again in the next quarter and beyond. And as demand fluctuates following the COVID-19 outbreak, companies have started taking precautionary measures to avoid supply-chain disruptions.

    Topic Coronavirus

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    EU Sees Drug Shortage Risk From COVID-19 Second Wave

    A second wave of COVID-19 infection later this year would put even greater pressure on drugs used in patients hospitalized with serious respiratory problems, a new report warns.

    Topic Coronavirus Distribution

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    European Industry Played Key Role In Mitigating COVID-19

    In the first part of an exclusive two-part interview, James Burt – Accord’s executive vice-president for Europe, the Middle East and North Africa – talks to Generics Bulletin about the key actions taken by the generics industry to mitigate the coronavirus pandemic, and the changed landscape that the off-patent arena can expect to see in future.

    Topic Coronavirus Manufacturing

  • Biomedtracker: 開発中医薬品をFDA承認確率で評価, Trialtrove: 医療用医薬品の臨床試験情報デ...

    COVID-19 Infographic

    COVID-19 Infographic

    Access the infographic below which explores the number of treatment drugs for COVID-19 currently in clinical trials or in development, events including progress updates, partnerships, regulatory and trial announcements etc, and the number of articles published on COVID-19 as of March 3, 2020. This data has been tracked and reported via Informa Pharma Intelligence’s clinical, regulatory and commercial data and analytics, and news and insight tools including Biomedtracker, Trialtrove, Pharmaprojects, Scrip, Pink Sheet, Medtech Insight, and Generics Bulletin etc.

    Topic Coronavirus

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Coherus Is Confident After US Ranibizumab Filing

    Having seen its development partner Bioeq file with the FDA in December last year, Coherus is confident that it will be a leader in the US biosimilar ranibizumab market targeting Lucentis.

    Topic biosimilars deal-trends

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Celltrion's Remsima SC Ready For Early 2020 Launch

    Celltrion says it is ready to roll out its Remsima SC subcutaneous infliximab in Europe in the first quarter of 2020, after receiving a formal pan-European marketing authorization from the European Commission.

    Topic Biosimilars Launches Regulation

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    California Plans To Create Own Generics Label

    California’s 2020-2021 fiscal budget includes plans to work with manufacturers to establish the state’s own generics label. But industry is sceptical that the initiative will deliver the savings that the US state hopes for.

    Topic Legislation policy-and-regulation

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Biocon’s Malaysia Insulin Facility Hit With 12 FDA Observations

    Biocon’s Malaysia Insulin Facility Hit With 12 FDA Observations

    The US FDA has slapped Biocon with a dozen observations over three units at its insulin manufacturing facility in Malaysia, but the Indian biotech firm says the problems can be remedied quickly and that US launch plans are on track for its insulin product glargine challenging French drug-maker Sanofi’s multi-billion-dollar Lantus.

    Topic fda diabetes biopharmaceutical

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Biocon Biologics Gets True North Investment

    Private equity group True North continues to back the Biocon group and is picking up a minority stake in Biocon Biologics in a deal that values the subsidiary at $3bn. Separately, another subsidiary, Biocon Biosphere, has also been set up as part of efforts to unlock the full potential of the business.

    Topic deal-trends strategy

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Alberta Is Second Canadian Province To Switch To Biosimilars

    Alberta has become the second Canadian province to announce a biosimilar switching program, following the example set by British Columbia earlier this year. The move has been welcomed by Biosimilars Canada but criticized by originator-backed body Crohn’s and Colitis Canada.

    Topic biosimilars Regulation

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Pfizer Reports 80% Biosimilars Growth In Q3

    pfizer biosimilars growth

    Pfizer has reported 80% growth in its global biosimilars business for the third quarter of 2020, on the back of recent oncology launches. Though the company’s sterile injectables saw a slight drop in business, Pfizer’s biopharma business saw 4% growth.

    Topic Coronavirus biosimilars deal-trends

  • HBW Insight : コンシューマーヘルスケア産業のニュース, Generics Bulletin: ジェネリック...

    Pharma Intelligence Launches Alexa Skill

    Pharma Intelligence Launches Alexa Skill

    Keep up with topics you care about in Pharma and Medtech with the new Alexa Skill from Informa Pharma Intelligence. Access daily news briefings to stay up to date with the latest news, right from your Alexa smartphone app!

    Topic Artificial Intelligence Consumer Innovation

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    EMA Endorses Dexamethasone For COVID-19

    Companies marketing dexamethasone in Europe have been told they can use a CHMP endorsement to request the addition of COVID-19 to their product license.

    Topic Coronavirus policy-and-regulation

医薬品産業専門のジャーナリスト&アナリスト

Management

Richard Faint

Management, Head of Medtech

UK

Richard Faint
Analyst

Chrystal Larsen

Analyst, Lead Market Analyst

USA

Chrystal Larsen

Chrystal specializes in

  • Medical Devices
  • Medtech
  • Metabolic
  • Neurology
  • Market intelligence

+25 year(s) experience

製品説明を兼ねた無料デモ&お問い合わせ

専任スタッフによる詳しい説明を兼ねた無料デモンストレーションを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。

新型コロナウイルス感染拡大防止のため在宅勤務を実施しています。お問合せの際は下記メールアドレスまたは各営業スタッフまでご連絡下さいますようご協力をお願い申し上げます。

インフォーマインテリジェンス合同会社
ファーマインテリジェンス
inquiry.jp@informa.com

*Omdia(ICT産業の情報)に関するお問い合わせはこちら
Contact_OmdiaJapan@omdia.com


オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。

お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。